eprintid: 1540763 rev_number: 52 eprint_status: archive userid: 608 dir: disk0/01/54/07/63 datestamp: 2017-02-11 22:59:07 lastmod: 2021-10-04 01:07:36 status_changed: 2017-08-11 10:34:25 type: article metadata_visibility: show creators_name: Thomas, JDJ creators_name: Dattani, A creators_name: Zemrak, F creators_name: Burchell, T creators_name: Akker, SA creators_name: Kaplan, FJL creators_name: Khoo, B creators_name: Aylwin, S creators_name: Grossman, AB creators_name: Davies, LC creators_name: Korbonits, M title: Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients ispublished: pub divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: G93 keywords: pituitary, acromegaly, cardiac magnetic resonance, renin-angiotensin note: Available under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) licence (https://creativecommons.org/licenses/by-nc-sa/4.0/). abstract: PURPOSE: Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood. METHODS: The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging. RESULTS: Patients taking ACEi/ARBs had lower end diastolic volume index (EDVi) and end systolic volume index (ESVi) than the other 2 groups ([C] 73.24 vs. [A] 97.92 vs. [B] 101.03 ml/m2, ANOVA p=0.034, B vs. C p<0.01). Groups A and B had EDVi and ESVi values at the top of published reference range values; Group C had values in the middle of the range. CONCLUSIONS: Acromegaly patients on ACEi/ARBs for hypertension demonstrate improved cardiac indices compared to acromegaly patients with hypertension not taking these medications. Further studies are needed to determine if these drugs have a beneficial cardiac effect in acromegaly in the absence of demonstrable hypertension. date: 2017-06 date_type: published official_url: http://dx.doi.org/10.1055/s-0042-123710 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green article_type_text: Journal Article verified: verified_manual elements_id: 1207742 doi: 10.1055/s-0042-123710 lyricists_name: Khoo, Bernard lyricists_id: BKHOO30 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner full_text_status: public publication: Experimental and Clinical Endocrinology & Diabetes volume: 125 number: 6 pagerange: 365-367 event_location: Germany issn: 1439-3646 citation: Thomas, JDJ; Dattani, A; Zemrak, F; Burchell, T; Akker, SA; Kaplan, FJL; Khoo, B; ... Korbonits, M; + view all <#> Thomas, JDJ; Dattani, A; Zemrak, F; Burchell, T; Akker, SA; Kaplan, FJL; Khoo, B; Aylwin, S; Grossman, AB; Davies, LC; Korbonits, M; - view fewer <#> (2017) Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients. Experimental and Clinical Endocrinology & Diabetes , 125 (6) pp. 365-367. 10.1055/s-0042-123710 <https://doi.org/10.1055/s-0042-123710>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/1540763/1/Thomas_Renin-Angiotensin_System_VoR.pdf